1.
Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery
systems. J Control Release. 2014;190:15-28.
2.
Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential.
Theranostics. 2016;6(9):1306-1323.
3.
Adepu S, Ramakrishna S, Costa-Pinto R, Oliveira AL. Controlled Drug Delivery Systems: Current
Status and Future Directions. Molecules. 2021;26(19):5905.
4.
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat
Rev Drug Discov. 2019;18(3):175-196.
5.
Almeida B, Nag OK, Rogers KE, Delehanty JB, Trabocchi A, Lenci E. Recent Progress in
Bioconjugation Strategies for Liposome-Mediated Drug Delivery. Molecules. 2020;25(23):5672.
6.
Liu J, Pandya P, Afshar S. Therapeutic advances in oncology. Int J Mol Sci. 2021;22(4):1-41.
7.
Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies.
Nat Biomed Eng. 2021;5(9):951-967.
8.
Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44(14):65186548.
9.
Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications.
Adv Drug Deliv Rev. 2021;178:113834.
10.
Paunovska K, Loughrey D, Dahlman JE, Coulter WH. Drug delivery systems for RNA therapeutics.
Nat Rev Genet. 2022;23(5):265-280.
11.
Azad RF, Brown-Driver V, Buckheit RW, Anderson KP. Antiviral activity of a phosphorothioate
oligonucleotide complementary to human cytomegalovirus RNA when used in combination with
antiviral nucleoside analogs. Antiviral Res. 1995;28(2):101-111.
12.
Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular
age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.
13.
Kastelein JJP, Wedel MK, Baker BF, et al. Potent Reduction of Apolipoprotein B and Low-Density
Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein
B. Circulation. 2006;114(16):1729-35.
14.
Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne
muscular dystrophy. Curr Opin Neurol. 2009;22(5):532-538.
15.
Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second
generation antisense inhibitor of apolipoprotein B Keywords antisense inhibitor, familial
hypercholesterolaemia, LDL-cholesterol, mipomersen. Br J Clin Pharmacol. 2013;76(2):269-76.
16.
Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci.
2017;20(4):497-499.
84
17.
Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B
vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed
hepatitis B vaccine in adults. Vaccine. 2018;36(5):668-674.
18.
Adams D, Gonzalez-Duarte A, O’Riordan, et al. Patisiran, an RNAi Therapeutic, for Hereditary
Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.
19.
Nasir Majeed C, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on Givosiran as a Treatment
Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug
Des Devel Ther. 2022;16:1827-1845.
20.
Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges.
Nat Rev Immunol. 2021;21(4):195-197.
21.
Yata T, Takahashi Y, Tan M, et al. Efficient amplification of self-gelling polypod-like structured
DNA by rolling circle amplification and enzymatic digestion. Sci Rep. 2015;5:14979.
22.
Ito K, Kariya M, Yasui K, Takahashi Y, Takakura Y. Development of Hydrophobic Interactionbased DNA Supramolecules as Efficient Delivery Carriers of CpG DNA to Immune cells. J Pharm
Sci. 2022;111(4):1133-1141.
23.
Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity
in vaccination. Nat Rev Immunol. 2012;12(7):479-491.
24.
Jorritsma SHT, Gowans EJ, Grubor-Bauk B, Wijesundara DK. Delivery methods to increase
cellular uptake and immunogenicity of DNA vaccines. Vaccine. 2016;34(46):5488-5494.
25.
Watson JD, Crick FHC. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic
Acid. Nature. 1953;171(4356):737-738.
26.
Fu Y, Wang X, Zhang J, Li W. Nanomaterials and nanoclusters based on DNA modulation. Curr
Opin Biotechnol. 2014;28:33-38.
27.
Linko V, Dietz H. The enabled state of DNA nanotechnology. Curr Opin Biotechnol.
2013;24(4):555-561.
28.
Seeman NC. Nucleic acid junctions and lattices. J Theor Biol. 1982;99(2):237-247.
29.
Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. Nature.
2006;440(7082):297-302.
30.
Chhabra R, Sharma J, Liu Y, Rinker S, Yan H. DNA Self-assembly for Nanomedicine. Adv Drug
Deliv Rev. 2010;62(6):617-625.
31.
Linko V, Ora A, Kostiainen MA. DNA Nanostructures as Smart Drug-Delivery Vehicles and
Molecular Devices. Trends Biotechnol. 2015;33(10):586-594.
32.
Mohri K, Nishikawa M, Takahashi N, et al. Design and development of nanosized DNA assemblies
in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells.
ACS Nano. 2012;6(7):5931-5940.
33.
Uno S, Nishikawa M, Mohri K, et al. Efficient delivery of immunostimulatory DNA to mouse and
85
human immune cells through the construction of polypod-like structured DNA. Nanomedicine.
2014;10(4):765-774.
34.
Mohri K, Nagata K, Ohtsuki S, et al. Elucidation of the Mechanism of Increased Activity of
Immunostimulatory DNA by the Formation of Polypod-like Structure. Pharm Res.
2017;34(11):2362-2370.
35.
Maezawa T, Ohtsuki S, Hidaka K, et al. DNA density-dependent uptake of DNA origami-based
two-or three-dimensional nanostructures by immune cells. Nanoscale. 2020;12:14818.
36.
Kimura Y, Sonehara K, Kuramoto E, et al. Binding of oligoguanylate to scavenger receptors is
required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem.
1994;116(5):991-994.
37.
Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotidebinding protein. Nat Med. 1997;3(4):414-420.
38.
Sirois CM, Jin T, Miller AL, et al. RAGE is a nucleic acid receptor that promotes inflammatory
responses to DNA. J Exp Med. 2014;211(5):1001-1001.
39.
Siess DC, Vedder CT, Merkens LS, et al. A human gene coding for a membrane-associated nucleic
acid-binding protein. J Biol Chem. 2000;275(43):33655-33662.
40.
Caminschi I, Meuter S, Heath WR. DEC-205 is a cell surface receptor for CpG oligonucleotides.
Oncoimmunology. 2013;2(3).
41.
Moseman AP, Moseman EA, Schworer S, et al. Mannose Receptor 1 Mediates Cellular Uptake and
Endosomal
Delivery
of
CpG-Motif
Containing
Oligodeoxynucleotides.
Immunol.
2013;191(11):5615-5624.
42.
Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of
oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994;269(43):26801-26805.
43.
Watanabe TA, Geary RS, Levin AA. Plasma Protein Binding of an Antisense Oligonucleotide
Targeting Human ICAM-1 (ISIS 2302). Oligonucleotides. 2006;16(2):169-180.
44.
Ohtsuki S, Takahashi Y, Inoue T, Takakura Y, Nishikawa M. Reconstruction of Toll-like receptor 9mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger
receptor 1 gene. Sci Rep. 2017;7(1):1-9.
45.
Sunagawa GA, Sumiyama K, Ukai-Tadenuma M, et al. Mammalian Reverse Genetics without
Crossing Reveals Nr3a as a Short-Sleeper Gene. Cell Rep. 2016;14(3):662-677.
46.
Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG
DNA in the lysosome. Nat Immunol. 2004;5(2):190-198.
47.
Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and immunity. Nat Rev
Immunol. 2013;13(9):621-634.
48.
Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. Cell. 2010;140(6):805-820.
49.
Doi T, Higashino KI, Kurihara Y, et al. Charged collagen structure mediates the recognition of
86
negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem.
1993;268(3):2126-2133.
50.
Baid K, Nellimarla S, Huynh A, et al. Direct binding and internalization of diverse extracellular
nucleic acid species through the collagenous domain of class A scavenger receptors. Immunol Cell
Biol. 2018;96(9):922-934.
51.
Matsumoto A, Naito M, Itakura H, et al. Human Macrophage Scavenger Receptors: Primary
Structure, Expression, and Localization in Atherosclerotic Lesions. Proc Natl Acad Sci U S A.
1990;87(23):9133-7.
52.
Gough PJ, Greaves DR, Gordon S. A naturally occurring isoform of the human macrophage
scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J
Lipid Res. 1998;39(3):531-543.
53.
Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752-3762.
54.
Zhu G, Liu Y, Yang X, et al. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
Nanoscale. 2016;8:6684.
55.
Chen W, Jiang M, Yu W, et al. CpG-Based Nanovaccines for Cancer Immunotherapy. Int J
Nanomedicine. 2021;16:5281-5299.
56.
Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 Blockade Resistance with CpG-A TollLike Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov.
2021;11(12):2998-3007.
57.
Zhang L, Zhu G, Mei L, et al. Self-Assembled DNA Immunonanoflowers as Multivalent CpG
Nanoagents. ACS Appl Mater Interfaces. 2015;7(43):24069-74.
58.
Roberto Mineo J, Vilanova M, Lang R, et al. CpG Oligodeoxynucleotides Induce Differential
Cytokine and Chemokine Gene Expression Profiles in Dapulian and Landrace Pigs. Front
Microbiol. 2016;7.
59.
Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert
Rev Vaccines. 2011;10(4):499-511.
60.
Nishikawa M, Ogawa K, Umeki Y, et al. Injectable, self-gelling, biodegradable, and
immunomodulatory DNA hydrogel for antigen delivery. J Control Release. 2014;180(1):25-32.
61.
Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B
vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed
hepatitis B vaccine in adults. Vaccine. 2018;36(5):668-674.
62.
Zhang H, Chen W, Gong K, Chen J. Nanoscale Zeolitic Imidazolate Framework-8 as Efficient
Vehicles for Enhanced Delivery of CpG Oligodeoxynucleotides. ACS Appl Mater Interfaces.
2017;9(37):31519-31525.
63.
Wei H, Zhao Z, Wang Y, Zou J, Lin Q, Duan Y. One-Step Self-Assembly of Multifunctional DNA
Nanohydrogels: An Enhanced and Harmless Strategy for Guiding Combined Antitumor Therapy.
87
ACS Appl Mater Interfaces. 2019;11(50):46479-46489.
64.
Ouyang X, Li J, Liu H, et al. Rolling Circle Amplification-Based DNA Origami Nanostructrures
for Intracellular Delivery of Immunostimulatory Drugs. Small. 2013;9(18):3082-3087.
65.
Ouyang X, Li J, Liu H, et al. Self-assembly of DNA-based drug delivery nanocarriers with rolling
circle amplification. Methods. 2014;67(2):198-204.
66.
Dembska A, Bielecka P, Juskowiak B. pH-Sensing fluorescence oligonucleotide probes based on
an i-motif scaffold: a review. Analytical Methods. 2017;9(43):6092-6106.
67.
Dong Y, Yang Z, Liu D. DNA Nanotechnology Based on i-Motif Structures. Acc Chem Res.
2014;47(6):1853-1860.
68.
Xu W, Huang Y, Zhao H, et al. DNA Hydrogel with Tunable pH-Responsive Properties Produced
by Rolling Circle Amplification. Chemistry. 2017;23(72):18276-18281.
69.
Padilla-Parra S, Matos PM, Kondo N, Marin M, Santos NC, Melikyan GB. Quantitative imaging
of endosome acidification and single retrovirus fusion with distinct pools of early endosomes. Proc
Natl Acad Sci U S A. 2012;109(43):17627-17632.
70.
Smith SA, Selby LI, Johnston APR, Such GK. The Endosomal Escape of Nanoparticles: Toward
More Efficient Cellular Delivery. Bioconjug Chem. 2019;30(2):263-272.
71.
Li T, Famulok M. I-Motif-Programmed Functionalization of DNA Nanocircles. J Am Chem Soc.
2013;135(4):1593-1599.
72.
Han DSC, Ni M, Chan RWY, et al. The Biology of Cell-free DNA Fragmentation and the Roles of
DNASE1, DNASE1L3, and DFFB. Am J Hum Genet. 2020;106(2):202-214.
73.
Chan MP, Onji M, Fukui R, et al. ARTICLE DNase II-dependent DNA digestion is required for
DNA sensing by TLR9. Nat Commun. 2015;6:5853.
74.
Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free
DNA in liquid biopsies. Science. 2021;372(6538).
75.
Lauková L, Konečná B, Janovičová ubica, Vlková B, Celec P. Deoxyribonucleases and Their
Applications in Biomedicine. Biomolecules. 2020;10(7):1036.
76.
Xu Y, Cheng M, Shang P, Yang Y. Role of IL‐6 in dendritic cell functions. J Leukoc Biol.
2022;111(3):695-709.
77.
Marcovecchio PM, Thomas G, Salek-Ardakani S. CXCL9-expressing tumor-associated
macrophages: new players in the fight against cancer. J Immunother Cancer. 2021;9(2):e002045.
78.
Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F. The potential of 1018 ISS adjuvant in hepatitis
B vaccines: HEPLISAV" review. Hum Vaccin Immunother. 2013;9(8):1661-1672.
79.
Garon EB, Spira AI, Johnson M, et al. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281,
a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–
small Cell Lung Cancer. Clin Cancer Res. 2021;27(16):4566-4573.
80.
Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin
88
Exp Allergy. 2003;33(10):1330-1335.
81.
Liu W, Ota M, Tabushi M, Takahashi Y, Takakura Y. Development of allergic rhinitis
immunotherapy using antigen-loaded small extracellular vesicles. J Control Release.
2022;345:433-442.
82.
Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That
Activates the Type I Interferon Pathway. Science. 2013;339(6121):786-791.
83.
Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA
mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12(10):959-965.
84.
Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an
activator of innate immune response. Nature. 2007;448(7152):501-505.
85.
Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular
DNA. Nat Immunol. 2010;11(11):997-1004.
86.
Unterholzner L. The interferon response to intracellular DNA: Why so many receptors?
Immunobiology. 2013;218(11):1312-1321.
87.
Jiang M, Jiang M, Chen P, et al. cGAS-STING, an important pathway in cancer immunotherapy. J
Hematol Oncol. 2020;13(1).
88.
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING agonists as cancer
therapeutics. Cancers (Basel). 2021;13(11).
89.
Zahid A, Ismail H, Li B, Jin T. Molecular and Structural Basis of DNA Sensors in Antiviral Innate
Immunity. Front Immunol. 2020;11:613039.
90.
Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS–STING signalling.
Nat Rev Mol Cell Biol. 2020;21(9):501-521.
91.
Ablasser A, Goldeck M, Cavlar T, et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second
messenger that activates STING. Nature. 2013;498(7454):380-384.
92.
Yildiz S, Alpdundar E, Gungor B, et al. Enhanced immunostimulatory activity of cyclic
dinucleotides on mouse cells when complexed with a cell‐penetrating peptide or combined with
CpG. Eur J Immunol. 2015;45(4):1170-1179.
93.
Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel).
2020;8(3):453.
94.
Taranejoo S, Liu J, Verma P, Hourigan K. A review of the developments of characteristics of PEI
derivatives for gene delivery applications. J Appl Polym Sci. 2015;132(25):42096.
95.
Petrovic M, Borchard G, Jordan O. Considerations for the delivery of STING ligands in cancer
immunotherapy. J Control Release. 2021;339:235-247.
96.
Li W. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug
and gene delivery. Adv Drug Deliv Rev. 2004;56(7):967-985.
97.
Nakase I, Kogure K, Harashima H, Futaki S. Application of a Fusiogenic Peptide GALA for
89
Intracellular Delivery. Methods Mol Biol. 2011;683:525-533.
98.
Morishita M, Takahashi Y, Nishikawa M, Ariizumi R, Takakura Y. Enhanced Class I Tumor Antigen
Presentation via Cytosolic Delivery of Exosomal Cargos by Tumor-Cell-Derived Exosomes
Displaying a pH-Sensitive Fusogenic Peptide. Mol Pharm. 2017;14(11):4079-4086.
99.
Hagino Y, Khalil IA, Kimura S, Kusumoto K, Harashima H. GALA-Modified Lipid Nanoparticles
for the Targeted Delivery of Plasmid DNA to the Lungs. Mol Pharm. 2021;18(3):878-888.
100.
Kawamoto Y, Liu W, Yum JH, et al. Enhanced Immunostimulatory Activity of Covalent DNA
Dendrons. ChemBioChem. 2022;23(4).
101.
Zinchuk V, Zinchuk O, Okada T. Quantitative Colocalization Analysis of Multicolor Confocal
Immunofluorescence Microscopy Images: Pushing Pixels to Explore Biological Phenomena. Acta
Histochem Cytochem. 2007;40(4):101-111.
102.
Renault K, Fredy JW, Renard PY, Sabot C. Covalent Modification of Biomolecules through
Maleimide-Based Labeling Strategies. Bioconjug Chem. 2018;29(8):2497-2513.
103.
Hansen RA, Märcher A, Gothelf KV. One-Step Conversion of NHS Esters to Reagents for SiteDirected Labeling of IgG Antibodies. Bioconjug Chem. 2022;33(10):1811-1817.
104.
Patel H, Tscheka C, Heerklotz H. Characterizing vesicle leakage by fluorescence lifetime
measurements. Soft Matter. 2009;5(15):2849.
105.
Vincent J, Adura C, Gao P, et al. Small molecule inhibition of cGAS reduces interferon expression
in primary macrophages from autoimmune mice. Nat Commun. 2017;8(1):750.
106.
Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP
Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell
Response. Immunity. 2018;49(4):754-763.e4.
107.
Corrales L, Glickman LH, McWhirter SM, et al. Direct Activation of STING in the Tumor
Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep.
2015;11(7):1018-1030.
108.
Jing W, McAllister D, Vonderhaar EP, et al. STING agonist inflames the pancreatic cancer immune
microenvironment and reduces tumor burden in mouse models. J Immunother Cancer.
2019;7(1):115.
109.
Harlin H, Meng Y, Peterson AC, et al. Chemokine Expression in Melanoma Metastases Associated
with CD8+ T-Cell Recruitment. Cancer Res. 2009;69(7):3077-3085.
110.
Henke E, Perk J, Vider J, et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition
of a transcriptional regulator in vivo. Nat Biotechnol. 2008;26(1):91-100.
111.
Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL. Intracellular delivery of an
antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res.
2010;38(19):6567-6576.
112.
Ämmälä C, Drury WJ, Knerr L, et al. Targeted delivery of antisense oligonucleotides to pancreatic
90
β-cells. Sci Adv. 2018;4(10).
91
...
論文の公開元へ
